Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Chief Financial Officer | May 02, 2023 | May 08, 2023 |
| Biomea Fusion, Inc.BMEA · Entity 6606 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date May 02, 2023 · Filed May 08, 2023
This filing explicitly reported no securities owned.
Biomea Fusion, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-06-09 | Direct | 173,711 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 173,711 · Balance 173,711 F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 173,711 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001193125-26-269465 · ownership.xml · derivative · entry 1 Averill Julianne · CIK 0001903770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,711 Underlying: Common Stock · 173,711 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:15 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 241,177 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0000950170-25-098343 · ownership.xml · derivative · entry 1 Averill Julianne · CIK 0001903770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,177 Underlying: Common Stock · 241,177 shares Expires 2035-07-21 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the total number of shares subject to the stock option shall vest and become exercisable on each monthly anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.